ABSTRACT: Obesity contributes to the genesis of many metabolic disorders including dyslipidemia, coronary heart disease (CHD), nonalcoholic fatty liver, type 2 diabetes, etc. Pancreatic lipase plays a vital role in food fat digestion and absorption. Therefore, to control obesity, inhibition of pancreatic lipase is the active therapy. Thus, novel natural product derived labdane appended triazoles with pancreatic lipase inhibition potential were designed and synthesized. Among these hybrids, 6b and 6f exhibited excellent inhibitory activity (IC 50 0.75 ± 0.02 μM and 0.77 ± 0.01 μM), slightly better than that of the positive control Orlistat (IC 50 0.8 ± 0.03 μM). Compounds 6c, 6e, and 6g−j inhibited the PL comparable to that of positive control. Interestingly none of the compounds showed cytotoxicity (Hep G2) in the concentration range from 0.5 to 100 μM. Overall results reveal the potential of labdane appended triazoles as antiobesity agents.
O besity is a medical condition with excess body fat accumulation to the extent which leads to serious health consequences. Obesity contributes to the genesis of many metabolic disorders, including dyslipidemia, 1 coronary heart disease (CHD), 2 nonalcoholic fatty liver, 3 type 2 diabetes, 4 etc. In 2017 WHO reported that global obesity has almost tripled since 1975. 5 As per literature, more than 340 million children and adolescents between 5 and 19 aged are overweight or obese. 5 As a result, physicians are prompted to take aggressive treatments in lifestyle changes, pharmacological interventions, and surgical therapies before a severe consequence becomes clinically apparent. Among these various treatments, pharmacotherapy is the most commonly used one. 6, 7 Pancreatic lipase plays a vital role in food fat digestion and absorption. 8 Therefore, to control obesity, inhibition of pancreatic lipase enzyme is the active therapy. Among the existing medicines, Orlistat is one such precise drug used for the inhibition of pancreatic lipase. In recent times, natural/ herbal products have also been considered as an alternative medicine for the treatment of obesity and related disorders. 9, 10 Many plant-based extracts have been reported for the treatment of obesity and associated diseases. For instance, ethanolic extracts of Terminalia paniculata showed very good antilipase and antiobesity activities. 11 Likewise, some terpenoid saponins from the leaves of Acantho panaxsenticosus, 12 the phenolic acids from fermented oats, 13 apple polyphenols, 14 and flavan-3-ol digalate esters of oolong tea are found to have substantial pancreatic lipase inhibitory properties. 15 Based on the traditional applications and its large medicinal properties in a long history of Ayurvedic medicine, we have selected Curcuma amada Roxb. for the exploration of its inhibition properties against the pancreatic lipase. C. amada, an edible ginger is one of the rhizomatous species in the Zingiberaceae family. The rhizomes of C. amada are a rich source of essential oils, and more than 130 phytochemicals are isolated, 16 which possess various biological properties, viz. antimicrobial, antioxidant, anti-inflammatory, anticancer, cardiovascular, and gastrointestinal disorders, etc. 16−19 Therefore, in continuation of our focused ongoing research interest in natural products and natural product based lead molecule 20−22 identification for therapeutic applications, in the present work, we have isolated the major compound (E)-Labda-8(17),12-diene-15,16-dial. This was synthetically transformed to rationally designed triazole appended analogues and evaluated for their pancreatic lipase inhibitory potential. The rationale for the targeted synthesis of triazole appended analogues is based upon its broad spectrum of biological properties. 23, 24 Triazole and pyrazole based synthetic drugs are also well-known for the treatment of obesity and related disorders (Figure 1) . 25−27 To begin with, the fresh rhizomes of 19, 28 A series of variously substituted triazole appended labdane derivatives were prepared by a three-step protocol starting from compound 1. When subjected to Jone's oxidation, one of the aldehydes of compound 1 is selectively oxidized into the acid derivative, Zerumin A (2). The alkyne intermediate (3) of Zerumin A is prepared in excellent yields by treating 2 with propargyl bromide (Scheme 1). The propargylated labdane undergoes the click reaction with various substituted benzyl and phenacyl azides (5) at room temperature to provide 1,2,3-triazole appended labdane derivatives (6a−q) in good to excellent yields (Scheme 2). All the synthesized derivatives are fully characterized by IR, NMR, and HRMS spectral data (Supporting Information).
The isolated E-labda-8(17),12-diene-15,16-dial (1), semisynthetic intermediates, and targeted triazole appendages were evaluated for the inhibitory activity against pancreatic lipase (PL) (Method A) 29 (Supporting Information). The parent molecule labdane dial exhibited moderate activity. Among those tested, the majority of the triazole hybrids showed strong PL inhibitory activity in the concentration ranging from 0.75 to 14.63 μM. Initially, the percentage of enzyme inhibition of compounds at various concentrations (1, 5, 10, and 20 μM) was evaluated. At lower concentration of 1 μM, compounds 6b and 6f showed inhibition of 75 to 80%. At 20 μM concentration the derivatives 6b, 6c, 6e, 6f, 6g, 6h, and 6j exhibited maximum inhibition percentage of 80 to 85 ( Figure  2 ). The other compounds (6a, 6k, 6l, 6m, and 6q) also showed better tendency to inhibit the PL. In contrast, few derivatives (6d, 6i, 6n, 6o, and 6p) failed to show any significant effect on pancreatic lipase. Overall, the labdanetriazole hybrids inhibited the PL through a concentration dependent manner.
Isolates and synthetic derivatives are tested at concentrations 1−20 μM. Each experiment was independently performed four times in duplicate and expressed as mean ± SD (n = 4).
In an attempt to validate the potential of the compounds, the PL inhibitory activity was repeated using human pancreatic lipase (Method B) 30 (Supporting Information). As expected, the compounds followed the similar trend in exhibiting the Table 1 .
The IC 50 results revealed (Method A) that the labdane traizole appendages 6b and 6f exhibited an excellent inhibitory activity with 0.75 ± 0.02 μM and 0.77 ± 0.01 μM, respectively, which is slightly better than that of positive control Orlistat (IC 50 0.8 ± 0.03 μM). Compounds 6c, 6e, and 6g−j inhibited the pancreatic lipase comparable to that of positive control in the range IC 50 0.8 to 0.9 μM, whereas, the parent molecule 1, semisynthetic intermediates 2 and 3, and labdane triazole derivatives 6a, 6k, 6l, and 6m showed moderate potency in the range of IC 50 5.35−14.63 μM. However, against the human pancreatic lipase (Method B), labdane triazole appendages 6b and 6f being the more potent analogues exhibited the inhibitory activities with IC 50 values 1.1 ± 0.53 μM and 1.25 ± 0.78 μM, respectively. Compounds 6c, 6e, and 6g−j also showed promising ability in inhibiting the PL with IC 50 values in the range of 1.65 to 2.31 μM. The parent molecule and other derivatives showed moderate activity. The preliminary studies also revealed that the compounds are bound to the active site of PL and probably exhibited a covalent interaction with PL. Nevertheless, extended kinetics and crystallographic studies are to be conducted for further authentication of a mode of interaction. We believe this is the first report on the pancreatic lipase inhibitory activity of labdane dial and its semisynthetic triazole appendages.
Isolates and synthetic derivatives are tested at concentrations 0.5−15 μM. Each experiment was independently performed four times in duplicate and expressed as means ± SD (n = 4).
From a structure−activity relationship point of view, we observed that the labdane-triazole hybrids incorporating benzyl azides (6a−l) were more active than the phenacyl azides (6m− q). Most of the analogues synthesized from benzyl azides exhibited excellent inhibition properties, slightly better than or equal to that of Orlistat. In contrast, the triazole analogues synthesized from phenacyl azides (6m−q) did not show any significant inhibition potential except for compound 6m. Precisely, among the triazoles incorporated from the variously substituted benzyl azides, all the para-substituted analogues showed the lowest IC 50 . However, the unsubstituted (6a), ortho-and meta-substituted benzyl azide incorporated triazole appendages showed moderate activity. Interestingly, there was no clear trend followed by the nature of the para substitution, i.e., among the halogen, electron donating, and electron withdrawing groups. Overall, among the various substituted hybrids 6b and 6f with p-F and p-Cl substituted benzyl azide incorporated triazole appendages were found to be the most potent candidates of the series.
Molecular docking studies have also been performed 31 in the present study to understand the basic knowledge on how these compounds have blocked human pancreatic lipase activity. There were 20 compounds docked on human pancreatic lipase to understand their possible binding site with respect to the binding energies of structure conformations of compounds ( Figure 4 ; Figure S , Supporting Information). The top ranked stable structure conformations on protein have shown the least Gibb's free binding energies. The docking results have shown that all the triazole derivatives are able to interact with lipase at the possible predicted site with different binding energies (Table S; Supporting Information). However, further experimental studies (i.e., site directed mutagenesis) are much 
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Letter needed to understand the precise mechanism of action of these compounds. This data provided us a vital clue about the interaction sites, which helps in our future in-depth studies toward lipase inhibition.
Further, in vitro toxicity of isolated and semisynthetic derivatives is carried out to analyze the effect of compounds on human liver cell lines. This method is primarily used to identify potentially hazardous compounds and their toxic effect in the early stage of development of therapeutic drugs. The cytotoxicity of compounds on Hep G2 human liver carcinoma-derived cell lines was measured by MTT assay. 32 The cytotoxic effect of each compound was estimated by calculating the percentage of cell viability in a dose-dependent manner ranging from 0.5 μM to 100 μM ( Figure 5 ). Based on the percentage of cell viability, compounds 6a, 6c, 6f, 6g, 6h, 6j, 6k, and 6q were found to be the least toxic on Hep G2 human liver cell lines, and none of the compounds showed any signs of toxicity at all the tested concentrations.
The cytotoxic effect of each compound is expressed as percentage of cell viability in a dose dependent manner. Values are mean ± SD of four independent experiments performed in duplicates.
In summary, a new series of natural product derived labdane-triazole hybrids were designed, synthesized, and evaluated for pancreatic lipase inhibitory potential. Among the semisynthetic derivatives, 6b and 6f are the most active candidates of the series with excellent PL inhibitory activity slightly higher than that of the positive control Orlistat. Hybrids 6c, 6e, and 6g−j inhibited the PL comparable to that of positive control. The structure−activity relationship studies suggested that the p-substitution on benzyl azides seems to be vital for improved PL inhibition. Cytotoxicity of the compounds on Hep G2 human liver carcinoma-derived cell line was measured by MTT assay. Based on the percentage of cell viability, none of the compounds showed any signs of toxicity at all the tested concentrations. This is the first report on the PL inhibitory activity of labdane dial and its semisynthetic triazole appendages. Our findings will provide useful insights for the design and synthesis of novel PL inhibitors. Presently, a detailed study to elucidate the molecular mechanistic action of an antiobesity effect of the compounds 6b and 6f by using in vitro and in vivo experimental models and structural optimization is in progress in our laboratory.
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